Golden Recursion Inc. logoGolden Recursion Inc. logo
Advanced Search
Kizzmekia S. Corbett

Kizzmekia S. Corbett

Kizzmekia (Kizzy) Corbett is an American viral immunologist.

All edits

Edits on 6 Oct, 2022
reynoldca barker"Edit from table cell"
reynoldca barker edited on 6 Oct, 2022
Edits made to:
Infobox (+1 properties)
Infobox
Megan Gustafson"rollback to version 39890847"
Megan Gustafson edited on 6 Oct, 2022
Edits on 7 Sep, 2022
Megan Gustafson"rollback to version 39383105"
Megan Gustafson edited on 7 Sep, 2022
Edits on 11 Aug, 2022
Megan Gustafson"rollback to version 38603540"
Megan Gustafson edited on 11 Aug, 2022
Edits made to:
Infobox (-1 properties)
Infobox
Edits on 5 Jul, 2022
Golden AI"remove blacklisted domain URLs"
Golden AI edited on 5 Jul, 2022
Edits made to:
Article
Article

In the summer term of 2005 (May-August), Corbett worked under Gloria Viboud, Ph.D., in a lab studying Yersinia pseudotuberculosis pathogenesis, the development of Yersinia pseudotuberculosis, which is a far-east scarlet fever-like ailment.

Edits on 20 Jun, 2022
Megan Gustafson
Megan Gustafson edited on 20 Jun, 2022
Edits made to:
Infobox (-1 properties)
Further Resources (+1 rows) (+4 cells) (+146 characters)
Further Resources

Title
Author
Link
Type
Date

Kizzmekia S. Corbett, PhD, details COVID-19 vaccine development & busting vaccine myths

Web

March 8, 2021

Infobox
Денис Доброчасов
Денис Доброчасов edited on 20 Jun, 2022
Edits made to:
Infobox (+1 properties)
Infobox
Edits on 3 Mar, 2022
Мария Филипова
Мария Филипова edited on 3 Mar, 2022
Edits made to:
Infobox (+1 properties)
Infobox
Edits on 12 May, 2021
Golden AI"Infobox creation from: Wikidata data enrichment"
Golden AI approved a suggestion from Golden's AI on 12 May, 2021
Edits made to:
Infobox (+1 properties)
Infobox
Doctoral advisor
Henry Ogolla
Henry Ogolla approved a suggestion from Golden's AI on 12 May, 2021
Edits made to:
Article (+3/-3 characters)
Article

During Corbett's time at the University of North Carolina at Chapel Hill, she focused on the dengue virus in Sri Lankan children under the supervision of Aravinda de Silva. Corbett studied the human response to the pathogens and the antibody production due to the dengue virus. Additionally, she studied how the virus DNADNA impacts the severity of cases. Corbett spent her off-campus fellowship in Sri Lanka as a visiting scholar with the Genetech Research Institute from April 2014 to May 2014. While in Sri Lanka, Corbett did follow-up exams on the children who provided initial samples for her research and obtained updated samples to study the antibody development further and write her dissertation that can be found here.

Edits on 12 May, 2021
Aime Anne Nisay
Aime Anne Nisay edited on 12 May, 2021
Edits made to:
Timeline (+1 events) (+155 characters)
Timeline

May 11, 2021

Kizzmekia S. Corbett joins the Harvard T.H. Chan School of Public Health as an assistant professor in the Department of Immunology and Infectious Diseases.
Edits on 17 Dec, 2020
Golden AI"Infobox creation from: Wikidata data enrichment"
Golden AI approved a suggestion from Golden's AI on 17 Dec, 2020
Edits made to:
Infobox (+1 properties)
Infobox
Google Scholar ID
Amy Tomlinson Gayle
Amy Tomlinson Gayle edited on 17 Dec, 2020
Edits made to:
Timeline
Article (+14/-9 characters)
Article

Kizzy Corbett was born on January 26, 1986, in Hurdle Mills, North Carolina, and is the daughter of Rhonda Brooks. Corbett and her family, which includes her mother;, step-father;, and six siblings, moved to Hillsborough, North Carolina after Corbett's fourth-grade teacher insisted Kizzy be placed on the "most demanding academic track possible."

...

Corbett received many acceptances to various colleges but accepted her offer from The University of Maryland because of her admittance into the Meyerhoff Scholars Program. In an interview with NBC News, Corbett stated she accepted the Meyerhoff offer because of the full-ride scholarship, the network, and the overall program.

...

Kizzy Corbett's science-related professional life began when she was in high school and has developed over the course of her education and professional experience.

...

At the age of fifteen, Corbett received an invitation to participate in Project SEED, an American Chemical Society merit-based summer experience program for economically disadvantaged teens interested in mathematics and science. She attended the program for two consecutive summers and was allowed to work in laboratories studying the chemistry of pharmaceuticals and other related fields.

...

In 2020, after the on-setonset of the Coronavirus global pandemic, Corbett began working on a vaccine for the novel coronavirus (COVID-19), at the NIH's Vaccine Research Center (VRC), after noticing the similarities between Severe Acute Respiratory Syndrome (SARS) and COVID-19. The team used prior knowledge of the coronavirus S proteins to begin working on a solution for COVID. Using Corbett's prior knowledge and assistance and collaboration from the University of Texas, at Austin, the teams transplanted stabilizing mutations from SARS-CoV S protein into SARS-CoV-2 spike proteins. Previously, Corbett had been a team member responsible for the cryogenic electron microscopy (CryoEM) structure of the SARS CoV-2 spike protein. This previous research suggested that messenger RNA (mRNA) encoding to S protein could be used to agitate the human immune response to produce antibodies against COVID.

Timeline

April 12, 2020

The woman leading COVID-19 vaccine trials is Kizzmekia Corbett.
Edits on 30 Nov, 2020
Erin Scherfner
Erin Scherfner edited on 30 Nov, 2020
Edits made to:
Table (+2/-2 rows) (+8/-5 cells) (+192/-265 characters)
Table

Title
Author
Link
Type
Date

Glycan repositioning of influenza hemagglutinin stem facilitates the elicitation of protective cross-group antibody responses

Web

2000

The duty to mentor, be visible and represent

Web

October 19, 2020

The duty to mentor, be visible and represent

Kizzmekia Corbett

Web

October 19, 2020

Erin Scherfner
Erin Scherfner edited on 30 Nov, 2020
Edits made to:
Table (+13/-6 rows) (+47/-29 cells) (+5165/-3754 characters)
Table

Title
Author
Link
Type
Date

A high-throughput inhibition assay to study MERS-CoV antibody interactions using image cytometry

Web

A high-throughput inhibition assay to study MERS-CoV antibody interactions using image cytometry

Osnat Rosen, Leo Li-Ying Chan, Olubukola M Abiona, Portia Gough, Lingshu Wang, Wei Shi, Yi Zhang, Nianshuang Wang, Wing-Pui Kong, Jason S McLellan, Barney S Graham, Kizzmekia S Corbett

Journal

March 1, 2019

A platform incorporating trimeric antigens into self-assembling nanoparticles reveals SARS-CoV-2-spike nanoparticles to elicit substantially higher neutralizing responses than spike alone

Web

2016

A platform incorporating trimeric antigens into self-assembling nanoparticles reveals SARS-CoV-2-spike nanoparticles to elicit substantially higher neutralizing responses than spike alone

Baoshan Zhang, Cara W. Chao, Yaroslav Tsybovsky, Olubukola M. Abiona, Geoffrey B. Hutchinson, Juan I. Moliva, Adam S. Olia, Amarendra Pegu, Emily Phung, Guillaume B. E. Stewart-Jones, Raffaello Verardi, Lingshu Wang, Shuishu Wang, Anne Werner, Eun Sung Yang, Christina Yap, Tongqing Zhou, John R. Mascola, Nancy J. Sullivan, Barney S. Graham, Kizzmekia S. Corbett & Peter D. Kwong

Journal

October 23, 2020

An mRNA Vaccine against SARS-CoV-2 -- Preliminary Report

Lisa A. Jackson, Evan J. Anderson, Nadine G. Rouphael, Paul C. Roberts, Mamodikoe Makhene, Rhea N. Coler, Michele P. McCullough, James D. Chappell, Mark R. Denison, Laura J. Stevens, Andrea J. Pruijssers, Adrian McDermott, Britta Flach, Nicole A. Doria-Rose, Kizzmekia S. Corbett, Kaitlyn M. Morabito, Sijy O'Dell, Stephen D. Schmidt, Phillip A. Swanson, Marcelino Padilla, John R. Mascola, Kathleen M. Neuzil, Hamilton Bennett, Wellington Sun, Etza Peters, Mat Makowski, Jim Albert, Kaitlyn Cross, Wendy Buchanan, Rhonda Pikaart-Tautges, Julie E. Ledgerwood, Barney S. Graham, John H. Beigel

Journal

November 12, 2020

Edits on 30 Nov, 2020
Erin Scherfner
Erin Scherfner edited on 30 Nov, 2020
Edits made to:
Table (+20 rows) (+99 cells) (+10432 characters)
Table

Title
Author
Link
Type
Date

An mRNA Vaccine against SARS-CoV-2 -- Preliminary Report

Lisa A. Jackson, Evan J. Anderson, Nadine G. Rouphael, Paul C. Roberts, Mamodikoe Makhene, Rhea N. Coler, Michele P. McCullough, James D. Chappell, Mark R. Denison, Laura J. Stevens, Andrea J. Pruijssers, Adrian McDermott, Britta Flach, Nicole A. Doria-Rose, Kizzmekia S. Corbett, Kaitlyn M. Morabito, Sijy O'Dell, Stephen D. Schmidt, Phillip A. Swanson, Marcelino Padilla, John R. Mascola, Kathleen M. Neuzil, Hamilton Bennett, Wellington Sun, Etza Peters, Mat Makowski, Jim Albert, Kaitlyn Cross, Wendy Buchanan, Rhonda Pikaart-Tautges, Julie E. Ledgerwood, Barney S. Graham, John H. Beigel

Journal

November 12, 2020

Burden of Dengue Infection and Disease in a Pediatric Cohort in Urban Sri Lanka

Hasitha Tissera, Ananda Amarasinghe, Aruna Dharshan De Silva, Pradeep Kariyawasam, Kizzmekia S. Corbett, Leah Katzelnick, Clarence Tam, G. William Letson, Harold S. Margolis, and Aravinda M. de Silva

Web

May 27, 2014

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Daniel Wrapp, Nianshuang Wang, Kizzmekia S. Corbett, Jory A. Goldsmith, Ching-Lin Hsieh, Olubukola Abiona, Barney S. Graham, and Jason S. McLellan

Web

Dengue type 1 viruses circulating in humans are highly infectious and poorly neutralized by human antibodies

ProfileRajendra Raut, Kizzmekia S. Corbett, Rashika N. Tennekoon, Sunil Premawansa, Ananda Wijewickrama, Gayani Premawansa, Piotr Mieczkowski, Claudia Rückert, Gregory D. Ebel, View ORCID ProfileAruna D. De Silva, and Aravinda M. de Silva

Web

December 5, 2018

Design of Nanoparticulate Group 2 Influenza Virus Hemagglutinin Stem Antigens That Activate Unmutated Ancestor B Cell Receptors of Broadly Neutralizing Antibody Lineages

Kizzmekia S. Corbett, Syed M. Moin, Hadi M. Yassine, Alberto Cagigi, Masaru Kanekiyo, Seyhan Boyoglu-Barnum, Sky I. Myers, Yaroslav Tsybovsky, Adam K. Wheatley, Chaim A. Schramm, Rebecca A. Gillespie, Wei Shi, Lingshu Wang, Yi Zhang, Sarah F. Andrews, M. Gordon Joyce, Michelle C. Crank, Daniel C. Douek, Adrian B. McDermott, John R. Mascola, Barney S. Graham, Jeffrey C. Boyington

Web

February 2019

Edits on 17 Nov, 2020
Erin Scherfner
Erin Scherfner approved a suggestion from Golden's AI on 17 Nov, 2020
Edits made to:
Article (+15/-15 characters)
Article

Kizzmeikia (Kizzy) Shanta Corbett is an American-born viral immunologist working at the National Institutes for Health (NIH) based in Bethesda, Maryland, as a research fellowresearch fellow in the Vaccine Research Center (VRC). Corbett is the scientific lead researcher for the VRC Coronavirus Team, researching possible vaccine solutions for the virus.

Erin Scherfner
Erin Scherfner approved a suggestion from Golden's AI on 17 Nov, 2020
Edits made to:
Article (+27/-27 characters)
Article

In the summer term of 2005 (May-August), Corbett worked under Gloria Viboud, Ph.D., in a lab studying Yersinia pseudotuberculosisYersinia pseudotuberculosis pathogenesis, the development of Yersinia pseudotuberculosis, which is a far-east scarlet fever-like ailment.

Erin Scherfner
Erin Scherfner approved a suggestion from Golden's AI on 17 Nov, 2020
Edits made to:
Article (+12/-12 characters)
Article

At the age of fifteen, Corbett received an invitation to participate in Project SEEDProject SEED, an American Chemical Society merit-based summer experience program for economically disadvantaged teens interested in mathematics and science. She attended the program for two consecutive summers and was allowed to work in laboratories studying the chemistry of pharmaceuticals and other related fields.

Erin Scherfner
Erin Scherfner approved a suggestion from Golden's AI on 17 Nov, 2020
Edits made to:
Article (+14/-14 characters)
Article

Corbett's team at the NIH VRC partnered with Moderna for vaccine development and manufacturing needs in 2020 and entered the Phase I clinical trialclinical trial 66 days after the virus sequence was released. The phase I trial was conducted using 45 people and two injections that were delivered 28 days apart.

Golden logo
By using this site, you agree to our Terms & Conditions.